Malaria (Plasmodium sp), a mosquito borne parasitic disease, is a major global killer with an estimated 863,000 deaths in 2008
(World Malaria Report). Currently half the world’s population is at risk with vulnerable groups such as young children, pregnant
women and the HIV infected of particular concern. Although prevention and treatment paradigms to control malaria have been in
place for many years these are dogged by numerous issues such as pathogen resistance, intervention availability and cost;
particularly in Sub-Saharan Africa.
The prospect of a malaria vaccine is appealing because large-scale mass vaccination (as conducted with other diseases) could be
implemented in Africa and make a significant impact. GSK Biologicals is developing Mosquirix (RTS, S) in Phase III studies across
Africa. Although the vaccine has relatively low efficacy (~40-50%) in preventing clinical episodes it is a major step forward for the
industry and is prompting other entities to pursue second generation approaches. RTS,S could be available in
This MarketVIEW product gives a comprehensive vaccine value ($USD/volume doses 000s) forecast of Malaria vaccines until 2030. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing efficacy scenarios.